Trial Profile
A Phase 2, Multi-dose, Double-blind, Active-controlled, Randomized Study to evlauate the safety, efficacy and Pharmacokinetic profile of Zabofloxacin at three dose regimens for patients with mild to moderate Community Acquired Pneumonia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs Zabofloxacin (Primary) ; Moxifloxacin
- Indications Bacterial infections; Community-acquired pneumonia
- Focus Therapeutic Use
- Sponsors Dong Wha Pharmaceutical
- 14 Sep 2012 New trial record